Cell-mediated immune status in patients with squamous cell carcinoma of the oral cavity by Saranath, Dhananjaya et al.
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Sixteen untreated patients with squamous cell carcinoma of the oral cavity were tested for in vhro 
immune status in comparison with the normal healthy donors. The parameters investigated were total 
leukocyte and lymphocyte counts, percentages and absolute counts of T- and B-cells in circulation, 
subsets of T-cells identified by the Fc receptors, phytohemagglutinin (PHA), and mixed lymphocyte 
culture (MLC) responses, natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) 
activities, and circulating immune complexes (CICs). Eight of these patients were retested 3 to 6 
months after surgery. The results showed that there was an increase in leukocyte and lymphocyte 
counts, an increase in the percentage and absolute number of B-lymphocytes, an increase in the 
percentage of T-gamma cells, suboptimal PHA and MLC responses, normal NK and ADCC activities, 
and increased levels of CICs in untreated oral cancer patients. In the postoperative stage, except for a 
reduction in leukocyte and lymphocyte counts, other abnormalities remained unchanged. The CICs in 
treated patients correlated with the tumor load in that in three patients showing recurrence, the CIC 
level remained elevated, whereas in patients without evidence of the disease the CIC level was either 
low or comparable to the upper normal limits. 
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N INDIA, a minimum of 40% of all cancers recorded I annually are cancers of the oral cavity and pharynx, 
based on hospital registry. ' J  This high incidence of 
cancers of the oral cavity has been attributed to the 
common habit of chewing betel leaf with areca nut, 
with or without tobacco.' Despite a predominance of 
oral cancers in India, there have been few investigations 
of the immune status of these  patient^.^-^ 
The current report deals with various immunologic 
parameters studied in patients with squamous cell car- 
cinoma of the oral cavity before and after surgery in 
comparison with normal healthy controls. The param- 
eters studied were absolute numbers of leukocytes and 
lymphocytes, absolute numbers and percentages of T- 
and B-lymphocytes and T-lymphocyte subsets, ability of 
T-lymphocytes to respond to mitogen phytohemagglu- 
tinin (PHA) and in mixed lymphocyte cultures (MLC), 
natural killer (NK) and antibody-dependent cellular 
cytotoxicity (ADCC) activities of peripheral blood lym- 
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phocytes, and levels of circulating immune complexes 
(CICs). 
Materials and Methods 
Patients and Controls 
Sixteen patients diagnosed as having primary squa- 
mous cell carcinoma of the oral cavity, aged 29 to 60 
years, were selected for the studies. The diagnosis was 
based on the clinical examination and histologic features 
of the biopsy material. In terms of the sites of the 
lesions, the majority of the patients under investigation 
had carcinoma of the buccal mucosa (seven) and carci- 
noma of the alveolous (five), whereas two patients had 
carcinoma of the tongue, and one patient each had 
carcinoma of the floor of the mouth and of the lip. The 
staging was done according to TNM classification, and 
patients with lesions in Stages T 1 to T4, NO or N 1, and 
MO and who were acceptable for surgery were studied. 
Eight of these patients were tested again after 3 to 6 
months of surgery. At the time of testing, three showed 
recurrence of the disease, whereas five had no evidence 
of the disease (NED). Sixteen normal healthy donors 
aged 26 to 50 years belonging to the laboratory personnel 
were used as controls. A count of total leukocytes and 
1062 
No. 5 CMI IN ORAL CANCER - Saranath et al. 1063 
lymphocytes per cubic millimeter of blood was done 
using routine methods. 
Preparation of Lymphocytes 
normal donor were stimulated with MMC-treated lym- 
phocytes from each other. Controls consisted of re- 
sponder cells alone and MMC-treated stimulator cells 
alone. Cultures were incubated for 144 hours in a 
Peripheral blood mononuclear cells (MNC) were col- 
lected according to the method described by Boyum6 
and suspended in RPMI-1640 buffered with 25 mM 
Hepes, containing 4 mM glutamine and antibiotics (50 
pg/ml streptomycin, 40pg/ml gentamicin, and 50 pg/ml 
Mycostatin [nystatin]), supplemented with either 10% 
heat-inactivated fetal calf serum (Difco, Detroit, MI) or 
10% heat-inactivated human AB serum (complete me- 
dium, CMFCS or CMAB, respectively). 
Total T- and B-Cell Population 
The T-lymphocyte population was studied by its 
ability to form spontaneous rosettes with sheep eryth- 
rocytes (S-RBC) as described by Jondal et aL7 whereas 
the percentage of B-lymphocytes was assessed by the 
ability to form EAC-rosettes as described by Bianco et 
al.' Absolute numbers of the T- and B-cells were cal- 
culated from the total leukocyte and the total lymphocyte 
counts. 
T-cell Subsets 
T-cell subsets were assessed by their ability to form 
rosettes with erythrocytes coated with ox-erythrocyte- 
specific IgG (Ty-rosettes) or IgM (Tp-rosettes) as de- 
scribed earlier.' 
Blastogenic Response to PHA and Allogeneic Cells 
Triplicate cultures with 2 X lo5 MNC/0.2 ml of 
CMAB per well of the microtest plate (Laxbro, India) 
were incubated with or without PHA ( 5  pg/ml, Burroughs 
Wellcome, UK) for 72 hours in humidified 5% C02  
atmosphere at 37 "C. Eighteen hours before harvesting, 
0.5 pCi of 3HTdR (specific activity 6-9 mCi/mM, 
BARC, Bombay, India) was added to each culture. The 
3HTdR incorporation by the cells of each well, harvested 
on Whatman No. 3 paper discs, was assessed on a 
Beckman LS 100 liquid scintillation counter. The mean 
counts per minute (CPM) in control cultures was sub- 
tracted from the CPM in PHA-treated cultures from 
each well to get the net CPM. 
Allogeneic mixed lymphocyte cultures were performed 
in triplicates using round-bottom microtiter plates (Lax- 
bro) with 2 X lo5 responder cells and 2 X lo5 cells 
treated with mitomycin C (MMC, 50 pg/6 X lo6 cells/ 
ml for 60 minutes at 37"C), in a total volume of 0.2 ml 
CMAB with additional 0.1 pM sodium pyruvate and 
5 X M 2-mercaptoethanol. In each experiment, 
lymphocytes from one oral cancer patient and one 
humidified atmosphere of 5% C02  at 37"C, and 1 pCi 
'HTdR was added to each well for the last 18 hours of 
the culture. Cells were harvested and the 3HTdR incor- 
poration was measured as before. The results were 
expressed as the percent response of the oral cancer 
patients relative to the response of normal healthy 
volunteers. Initial experiments, in which responding 
lymphocytes from normal donors were stimulated with 
MMC-treated cells from one oral cancer patient and 
two normal allogeneic donors, confirmed that the stim- 
ulatory ability of lymphocytes from oral cancer patients 
was within the normal range. 
Eflector Cells for NK and ADCC Activity 
Lymphocyte-rich MNCs suspended at 5 X lo6 cells/ 
ml in CMFCS were depleted of adherent cells by plastic 
adherence of the MNC. The nonadherent cells were 
cultural overnight in CMFCS (20% FCS) and used as 
effectors the next day." 
NK Cytotoxicity 
The cultured human erythroleukemic cell line K562 
was used as targets. One million viable K562 cells in 
growth phase were labeled by the addition of 100 pCi 
of sodium chromate (Na251Cr04, specific activity 1 mCi/ 
ml, BARC), and incubated for 1 hour at 37"C, with 
occasional shaking." The cells were then washed three 
times and resuspended at a concentration of 1 X lo5/ 
ml in CMFCS and checked for viability. Three effector: 
target ratios, which were 50:1, 25:1, and 12.5:1, were 
tested in triplicates in a 4-hour incubation assay. For 
maximum uptake, radioactivity incorporated in I X lo4 
target cells, a concentration used per replicate in the 
assay, was counted directly. The percentage of cytotox- 
icity for each replicate was calculated from the following 
formula to find out the mean percent cytotoxicity. 
% cytotoxicity 
x 100 
maximum uptake - spontaneous release 
The range of spontaneous release of label from 1 X lo4 
target cells at the end of 4 hours of incubation was 3% 
to 12%. 
- experimental release - spontaneous release - 
Antibody-Dependent Cellular Cytotoxicity 
Chicken erythrocytes (CRBCs) were freshly collected 
and used as target cells.'' Twenty million CRBCs were 
labeled with 100 pCi of "Cr as described earlier. After 
- 
16- - 
14-  
- 
12- 
- 
10 - 
- 
8 -  
- 
6 -  
- 
4 -  - 
2- 
w 
k 
u 
0 
I 
Q 
L 
. 5 -  
8 -  
7 -  
6 -  
5 -  
4 -  
3- 
2-  
'1 
CANCER September I 1985 Vol. 56 
.e 
0 
4.674 k0.42 
P< 0.01 FIG. I .  Leukocyte and lymphocyte counts 
of untreated oral cancer patients and normal 
0 M 
0 
0 
0 
: individuals. 
* 
O R A L  
C A N  C E R 
ORAL 
CANCER 
n=16 ns  16 ns16 n=16 
labeling and washing, CRBCs were resuspended at a 
concentration of 1 X lo6 cells/ml. In I X lo5 target cells, 
100 pl of 1:lOOO dilution of rabbit anti-CRBC serum 
and 1 X lo6 effector cells were added. Test controls did 
not contain the antisera. Incubation, harvesting, and 
calculation of specific chromium release was carried out 
in the same way as that of NK cytotoxicity. 
comparison with those of 16 healthy controls. It was 
observed that oral cancer patients showed a significant 
increase in the leukocyte count (9879 f 800) and lym- 
phocyte count (4674 f 420) in the peripheral blood, 
compared with normal donors (6120 iz 430 and 2698 
f 230, respectively). 
Lymphocyte Subpopulations Circulating Immune Complexes 
Circulating immune complexes were assessed by a 
fluid phase radioiodinated C 1 q binding assay as described 
earlier. l 2  Heat-aggregated human gamma globulin (AHG) 
at various concentrations was used as positive control, 
and the World Health Organization (WHO) supplied 
AHG standards (kindly given by Dr. U. Nydegger) 
(WHO, Immunology Research and Training Centre, 
Geneva) that were used for provisory reference curve. 
Results were expressed as percent Clq binding activity 
(CIq-BA) as well as pg/ml AHG equivalent. 
Results 
Leukocyte and Lymphocyte Counts 
The total leukocyte and lymphocyte counts from 16 
untreated oral cancer patients are shown in Figure 1, in 
Figure 2 shows the percentage of T- and B-lymphocytes 
in the peripheral blood of untreated oral cancer patients. 
A significant elevation in the percentage of B-lympho- 
cytes was shown by oral cancer patients (39 f 2.6) 
compared with controls (30 f 1.6), whereas the percent- 
age of T-lymphocytes appeared to be equivalent to that 
of normal controls (52 k 2.1 and 50 f 2.4, respectively). 
Since the total lymphocyte count of oral cancer patients 
was increased, the absolute values of total B-lymphocytes 
in patients showed further increase (1784 f 204) in 
comparison with healthy donors (709 k 77, P < 0.001). 
Similarly, there was a significant difference in the absolute 
number of T-lymphocytes in oral cancer patients (2432 
f 240) when compared with controls ( 1  165 f 99, P 
< 0.00 1) because of differences in total lymphocyte 
count in circulation. 
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pared with normal controls (Ty, 22 k 3.0; Tp, 41 
k 4.2). However, the absolute numbers of regulatory T- 
cells in circulation again showed variation. The total 
number of Ty-cells in circulation in cancer patients 
(574 k 94) was significantly greater than in controls (252 
k 34, P < 0.001). Also, the total number of Tp-cells in 
the peripheral blood of oral cancer patients (955 & 1 15) 
TABLE 1. NK Cytotoxicity and ADCC of Peripheral Blood 
Lymphocytes From Untreated Oral Cancer Patients 
and Normal Individuals 
NK activity % specific 
cytotoxicity at 
ET* 
50: 1 
25: I 
1251  
ADCC 70 specific 
cytotoxicity at 
E:Tt 
1O:l 
Normal donor Oral cancer patients 
(n = 16) 
(X _+ SE) 
( F  = 16) 
(X _+ SE) 
39.0 k 4.0 
25.0 k 3.0 
15.3 _+ 3.4 
34.0 f 4.4 NS 
23.1 f 3.5 NS 
14.0 k 2.5 NS 
49.8 k 3.9 49.2 f 4.4 NS 
~~ 
* Targets: K562. 
t Targets: chicken erythrocytes. 
NK: natural killer cell; ADCC antibody-dependent cellular cytotox- 
icity; SE: standard error; E:T: effectortarget ratio; NS: not significant. 
n =I6 
FIG. 4. Response of untreated cancer 
patients and normal individuals to PHA 
and allogeneic cells. *Response to PHA 
statistically analyzed using Wilcoxon's 
matched-pairs signed-ranks test. 
showed significant elevation above that of normal con- 
trols (462 f 90, P < 0.01). Since both subsets showed 
elevation, the Tp:Ty ratios were not significantly altered. 
Blastogenic Response to PHA and Allogeneic Cells 
Figure 4 illustrates the 3HTdR incorporation of lym- 
phocytes from oral cancer patients and normal donors 
after stimulation with PHA and allogeneic cells. The 
PHA responsiveness of lymphocytes from controls and 
patients, conducted simultaneously, was evaluated sta- 
tistically using Wilcoxon's matched-pairs signed-rank 
test, whereas the ability of lymphocytes from cancer 
patients to respond to alloantigens was expressed in 
terms of percent relative response in relation to response 
of normal lymphocytes stimulated simultaneously. As 
can be seen from Figure 4, lymphocytes from oral cancer 
patients showed reduced response to PHA. Also, 11 of 
16 (70%) patients showed reduced values of percent 
relative response in MLC, the response varying between 
7% and 79% of that of normal lymphocytes. 
NK and Antibody-Dependent Cellular Cytotoxicity 
Peripheral blood lymphocytes from 16 oral cancer 
patients and 16 normal donors were tested for NK and 
ADCC activities, as summarized in Table 1. It was seen 
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that the untreated oral cancer patients had NK and 
ADCC activities equivalent to those of normal individ- 
uals. 
Circulating Immune Complexes 
The C 1 q-BA of sera from I6 oral cancer patients and 
normal donors is summarized in Figure 5. A large 
number of normal sera were tested for Clq-BA to get 
the mean percent binding activity and to establish upper 
limits, since the normal Indian population shows con- 
siderable variation in CICs. Sixteen controls used in the 
current study have been included in these data. As 
compared with sera from 50 normal healthy individuals 
who showed percent Clq-BA to the level of 8.8 _+ 0.82, 
the group mean values of serum Clq-BA was significantly 
increased in the oral cancer patient (25.4 -t 3.6, P 
< 0.001). The upper limit of controls (mean + 2 standard 
deviations [SD]) was established at 19.66% for the 50 
control sera, as shown in the scattergram (Fig. 5). Within 
this group, Clq-BA was not detected in 6 of 50 (12%) 
sera samples, and 2 of 50 (4%) tests showed values 
greater than the upper limit. Elevated Clq-BA was 
observed in 11 of 16 (68.7%) oral cancer patients. 
With several batches of Clq, the variation in the Clq- 
BA measured on an internal standard was relatively 
limited. The interassay coefficient of variation was 8%, 
at 34% C 1 q-BA. 
Comparison of Immune Parameters Before 
and After Surgery 
Table 2 gives the comparative data on the same 
immune parameters studied on eight patients 3 to 6 
months after surgery. With each blood sample of the 
follow-up patient, a blood sample from one normal 
healthy donor was tested as before. As indicated in the 
table, three patients showed recurrence of the disease at 
the time of retesting. 
The major deviations in the immune parameters of 
preoperative oral cancer patients were increased leukocyte 
and total lymphocyte counts, increased levels of B- 
lymphocytes and Ty-cells, and decreased PHA and 
MLC responses. It appears that in most of the cases 
there was a postoperative reduction in total leukocyte 
and lymphocyte counts. However, the B-cell proportions 
showed recovery only in three cases, whereas recovery 
was seen in percentage and absolute number of Ty-cells 
only in one patient. The same patient showed improve- 
ment in PHA response after surgery; however, the 
relative MLC response was still low after surgery (Patient 
ARI 2204). In fact, none of the follow-up patients tested 
for MLC showed improvement of reactivity in compar- 
ison with simultaneously studied controls. The low NK 
activity in Patient AR4807 was boosted considerably 
after treatment, whereas that of Patient AR 12204 was 
reduced. The CICs appeared to be either reduced or 
maintained at the upper limit of normal values (i.e., 
19.66) postoperatively in NED patients, whereas they 
were still increased in three patients with recurrence. In 
fact, Patient AR5233, who had shown a low Clq-BA 
value preoperatively, shwoed increased CICs and recur- 
rence when tested again. This appeared to be the only 
parameter that distinguished patients with recurrent 
from those with nonrecurrent disease. The data from 
Table 2 thus show that there was no appreciable recovery 
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of abnormalities when oral cancer patients were retested 
after surgery. 
Discussion 
Impairment of cell-mediated immunity measured in 
vitro has been reported in patients with squamous cell 
carcinoma of the head and neck region.l3-I8 These 
studies involve measurement of percentage and absolute 
numbers of lymphocyte populations and/or their mitogen 
and alloantigen  response^.'^*^^-^' Ca ncer of the oral 
cavity is a very predominant type of cancer in India.'*2 
Some studies on tumor-associated antigen responses of 
oral cancer patients3 and their ability to respond to 
recall antigens in vivo and PHA in vitro4 have been 
reported by us before. It is now known that interactions 
of regulatory and effector cells are the major contributory 
factors for the normal immune functions. While assessing 
the immune status, it is therefore necessary to study 
these cellular components simultaneously. In this article, 
we report a number of in vitro parameters of immune 
status simultaneously in patients with cancer of the oral 
cavity in comparison with normal healthy donors. We 
also attempted to determine if the deviations from the 
normal responses are normalized after surgical therapy 
and their relationship to the recurrence of the disease 
in a small group of follow-up patients. 
Several workers have reported decreased percentage 
and total T-lymphocyte counts in oral cancer  patient^,'^,^' 
whereas our data show that there was a significant 
increase in total leukocyte and lymphocyte counts in 
untreated oral cancer patients. Although the percentages 
of T-lymphocytes in our studies were comparable to 
those of normal donors, their absolute numbers were 
elevated because of the increased absolute lymphocyte 
numbers. Similar discrepancies in the total numbers and 
percentages of lymphocyte populations have been re- 
ported b e f ~ r e . ' ~ , ' ~  It appears that the percentages of T- 
lymphocytes in oral cancer patients as well as in controls 
reported by us are lower than those normally reported. 
This could be because we have not used neuraminidase- 
treated SRBCs for rosetting, which is known to improve 
the rosette formation. However, in studies conducted 
by Bier et a1.,19 similar low numbers of T-lymphocytes 
are reported in controls (53%) and in oral cancer patients 
(39%). Also, we observed a major imbalance in the 
percentage and absolute numbers of B-lymphocytes in 
oral cancer patients in contrast with the decreased values 
reported before.21.22 Since we used the EAC-rosette 
technique for enumeration of B-cells, it is possible that 
we may have counted some monocytes along with the 
B-cells, both in controls and in oral cancer patients. 
However, the increase is higher than that accountable 
by monocyte contamination. 
For the analysis of subsets of T-lymphocytes we have 
used IgG FcR and IgM FcR as markers. Recently, the 
use of monoclonal antibodies for the assessment of T- 
lymphocyte phenotyes has been more popular. However, 
as shown by Ballieux and He i jne r~ ,~~  both of these 
methods detect overlapping populations. For example, 
approximately 40% of the Ty-cells express OKT8 marker, 
whereas approximately 40% of the OKT8 positive cells 
form E(0X)-IgG rosettes. Since Ty- and Tp-cells have 
been shown to conduct suppressor and helper functions, 
re~pectively,'~ we have used these markers to identify 
subsets of T-lymphocytes. Our observations on the 
subsets of T-lymphocytes indicate the normal percentages 
of the regulatory cells in oral cancer patients; however, 
the absolute number of cells in the helper as well as 
suppressor population were increased. Decreased lym- 
phocyte proliferative response to PHA'4,15-18*22 as well as 
MLC13 in oral cancer patients has been reported by 
others, although no attempt has been made to correlate 
these reduced functions with an imbalance in the regu- 
latory cells in circulation. Our studies showed that since 
there was an increase in absolute counts of both regu- 
latory cells, the reduced T-cell function may not be 
attributable to the imbalance in Tp:Ty ratio. We are 
currently investigating whether generation and/or re- 
sponse to interleukins could contribute to the deficient 
T-cell function in oral cancer. 
Another discrepancy noted by us in the T-cell subset 
studies was that in some instances the addition of Ty- 
and Tp-cell percentages exceeded 100 (Table 2). This 
could be a result of occasional expression of dual 
receptors, as suggested by Pichler and B r ~ d e r . ~ ~  
It appears from our studies that the NK and ADCC 
activities of oral cancer patients are within the normal 
range. These effector mechanisms have not been studied 
in oral cancer patients, although increased cytotoxicity 
of patients' lymphocytes to squamous cell carcinoma 
cell lines has been reported.2s 
We have also reported here increased CICs in untreated 
oral cancer patients, which is in accordance with the 
observations reported by Scully et a1.26 Whether the 
increased number of B-lymphocytes represents a hyper- 
active humoral responsiveness, perhaps leading to an 
increased number of CICs, is difficult to assess. On the 
other hand, an increased number of CICs might reflect 
the tumor burden of the patient to a certain degree, 
which has been reported repeatedly," and which is also 
evident from the observation that patients with nonre- 
current diseases postoperatively showed fewer CICs in 
circulation. 
Thus, the major deviations in immune parameters in 
oral cancer patients appear to be increased leukocyte 
and lymphocyte counts, increased B- and Ty-cells, de- 
creased PHA and MLC responses, and increased levels 
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of CICs. Individual comparisons between the immune 
parameters pre- and postoperatively indicate that the 
major abnormalities in regulatory cells and T-cell func- 
tions still persisted postsurgery and they did not correlate 
with the load of tumor in the patients. Bier et af.I9 have 
also reported that there is no correlation between the 
clinical course of the disease and nonspecific immune 
reactivity in patients with head and neck cancer. The 
only parameter that apparently correlated with the tumor 
burden was the level of CICs. 
REFERENCES 
I .  Desai PB. Clinical cancer research in India: Present status and 
future prospects. Indian J Med Res 1983; 78(suppl):8-28. 
2. Sanghavi LD. Cancer epidemiology: The Indian scene. J Cancer 
Res Clin Oncol I98 I ; 99: 1 - 14. 
3. Nair PN, Gangal SG, Rao RS. Studies on irnmunotherapy in 
oral cancer patients with BCG and tumor antigens. Indian J Med Res 
4. Rao RS, Fakih AR, Nair CN, Naik SL, Gangal SG. Evaluation 
of cellular immunity in oral cancer patients in India. Indian J Cancer 
(in press). 
5 .  Balaram P, Vasudevan DM. Quantitation of Fc receptor bearing 
T-lymphocytes (TG and TM) in oral cancer. Cancer 1983; 52:1837- 
1840. 
6. Boyum A. Isolation of mononuclear cells and granulocytes from 
human blood. Scand J Clin Lab Invest [Suppl] 1968; 2 1:77-89. 
7. Jondal M, Holm G, Wigzell H. Surface markers on human T- 
and B-lymphocytes. J Exp Med 1972; l36:207-2 15. 
8. Bianco C, Patrick R, Nussenzweig V. A population of lymphocytes 
bearing a membrane receptor for antigen-antibody-complement com- 
plexes. J Exp hfed 1970; 132:702-720. 
9. Karande AA, Gulwani B, Advani SH, Gangal SG. Sub-populations 
of human T-lymphocytes in patients with Hodgkin’s disease before 
and after treatment. Neoplasma 1982; 29: 149-1 59. 
10. Steinhauer EH, Doyle AT, Reed J, Kadish AS. Defective natural 
cytotoxicity in patients with cancer: Normal number of effector cells 
but decreased recycling capacity in patients with advanced disease. J 
Immunol 1982; 129:2255-2259. 
11 .  Perlmann P, Perlmann H. Contactual lysis of antibody coated 
chicken erythrocytes by purified lymphocytes. Cell Immunol 1970; 1: 
1978; 701252-262, 
300-306. 
12. Saranath D, Advani SH, Gangal SG. Circulating immune 
complexes in chronic myeloid leukemia patients at various stages of 
the disease.Leuk Res 1983; 7:77 1-777. 
13. Berlinger NT, Hilal EY, Oettgen HF, Good RA. Deficient cell 
mediated immunity in head and neck cancer patients secondary to 
autologous suppressive immune cells. Laryngoscope 1978; 88:470-483. 
14. Chretien PB, Twomey PL, Catalona WJ, Hansing RL. Immu- 
nologic defects associated with squamous cell carcinoma. Cancer 1975; 
15. Papenhausen PR, Kukwa A, Croft CB, Borowiecki B, Silver C, 
Emerson EE. Cellular immunity in patients with epidermoid cancer 
of head and neck. Laryngoscope 1979; 89538-549. 
16. Scully C. The immunology of cancer of the head and neck with 
particular reference to oral cancer. Oral Pathol 1982; 53: 157-169. 
17. Stefani S, Kerman R, Abbate J. Serial studies on immunocom- 
petence in head and neck cancer patients undergoing radiation therapy. 
Am J Roentgenol 1976; 126:880-886. 
18. Zighelboim J, Doren F, Parker NH, Calcaterra T, Ward P, 
Fahey J. Immunologic evaluation of patients with advanced head and 
neck cancer receiving weekly chemo-irnmunotherapy. Cancer 1979; 
19. Bier J, Nicklisch U, Platz H. The doubtful relevance of nonspecific 
immune reactivity in patients with squamous cell carcinoma of the 
head and neck region. Cancer 1983; 52:1165-1172. 
20. Eastham RJ, Mason JM, Jenning BR, Belew PW, Maguda TA. 
T-cell rosette test in squamous cell carcinoma of the head and neck. 
Arch Otolaryngol 1976; 102:171-175. 
21. Stefani SS, Kerman RH. Lymphocyte response to PHA before 
and after radiation therapy in patients with carcinoma of the head and 
neck. J Laryngol Otol 1977; 91:605-609. 
22. Wanebo HJ, Jun MY, Strong EW, Oettgen H. T-cell deficiency 
in patients with squamous cell cancer of head and neck. Am J Surg 
23. Ballieux RE, Heijnen CJ. Immunoregulatory T-cell subpopula- 
tions in man: Dissection by monoclonal antibodies and Fc receptors. 
Immunol Rev 1983; 745-28. 
24. Pichler WJ, Broder S. In vitro functions of human T-cells 
expressing Fc-IgG and Fc-IgM receptors. Immunol Rev 1981; 56: 163- 
197. 
25. Ariyan S, Krizek TJ, Mitchell MS. Identification of squamous 
cell carcinoma of the head and neck by tissue culture and immunological 
testing. Plast Reconstr Surg 1977; 59:386-393. 
26. Scully C, Barkas T, Boyle P, McCregor IA. Circulating immune 
complexes detected by binding of radiolabelled protein A in patients 
with oral cancer and oral premalignant lesions. J Clin Lab Immunol 
36: 13-18. 
44:117-123. 
1975; 130:445-45 I .  
1982; 8:113-115. 
